Kazuhiro Kitajima Kitajima

Dr. Kazuhiro Kitajima Kitajima


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
KKKazuhiro Kitajima Kitajima
Kazuhiro Kitajima Kitajima
MOMasaya Okada
Masaya Okada
KYKyoko Yoshihara
Kyoko Yoshihara
TTTazuko Tokugawa
Tazuko Tokugawa
ASAkihiro Sawada
Akihiro Sawada
KYKoichiro Yamakado
Koichiro Yamakado
Oncotarget | https://doi.org/10.18632/oncotarget.27103 Kazuhiro Kitajima, Masaya Okada, Kyoko Yoshihara, Tazuko Tokugawa, Akihiro Sawada, Satoshi Yoshihara, Hiroya Tamaki, Yoshihiro Fujimori, Syuji Ueda, Hiroyuki...

26 November 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
KKKazuhiro Kitajima Kitajima
Kazuhiro Kitajima Kitajima
MHMasaki Hashimoto
Masaki Hashimoto
TKTakayuki Katsuura
Takayuki Katsuura
NKNobuyuki Kondo
Nobuyuki Kondo
TMToshiyuki Minami
Toshiyuki Minami
KYKoichiro Yamakado
Koichiro Yamakado
Oncotarget | https://doi.org/10.18632/oncotarget.27324 Kazuhiro Kitajima, Masaki Hashimoto, Takayuki Katsuura, Nobuyuki Kondo, Toshiyuki Minami, Kozo Kuribayashi, Seiki Hasegawa, Takashi Kijima, Koichiro Yamakado

4 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KKKazuhiro Kitajima Kitajima
Kazuhiro Kitajima Kitajima
MMMitsunari Maruyama
Mitsunari Maruyama
HYHiroyuki Yokoyama
Hiroyuki Yokoyama
TMToshiyuki Minami
Toshiyuki Minami
TYTakashi Yokoi
Takashi Yokoi
KYKoichiro Yamakado
Koichiro Yamakado
Background: To compare three FDG-PET criteria (EORTC, PERCIST, imPERCIST) with CT criteria (combined modified RECIST and RECIST 1.1) for response evaluation and prognosis prediction in patients with recurrent MPM treated with ICI monotherapy. Methods: Thirty MPM patients underwent FDG-PET/CT and contrast-enhanced CT at the baseline and during nivolumab therapy (median 10 cycles). Therapeutic response was evaluated according to EORTC, PERCIST, imPERCIST, and CT criteria. PFS and OS were examined using log-rank and Cox methods. Results: CMR/PMR/SMD/PMD numbered 5/3/4/18 for EORTC, 5/1/7/17 for PERCIST, and 5/3/9/13 for imPERCIST. With CT, CR/PR/SD/PD numbered 0/6/10/14. There was high concordance between EORTC and PERCIST (κ = 0.911), and PERCIST and imPERCIST (κ = 0.826), while that between EORTC and imPERCIST (κ = 0.746) was substantial, and between CT and the three PET criteria moderate (κ = 0.516–0.544). After median 14.9 months, 26 patients showed progression and nine died. According to both PET and CT findings, patients with no progression (CMR/PMR/SMD or CR/PR/SD) showed significantly longer PFS and somewhat longer OS than PMD and PD patients (EORTC p = 0.0004 and p = 0.055, respectively; PERCIST p = 0.0003 and p = 0.052; imPERCIST p < 0.0001 and p = 0.089; CT criteria p = 0.0015 and p = 0.056). Conclusions: Both FDG-PET and CT criteria are accurate for response evaluation of ICI therapy and prediction of MPM prognosis. In comparison with CT, all three FDG-PET/CT criteria judged a greater percentage of patients (16.7%) as CMR, while two (EORTC, PERCIST) judged a greater percentage (10–13.3%) as PMD. For predicting PFS, the three FDG-PET criteria were superior to the CT criteria, and imPERCIST demonstrated the highest rate of accurate prediction.

6 October 2020 in Oncotarget
Verified
Journal Article
Open access
PDF file
KKKazuhiro Kitajima Kitajima
Kazuhiro Kitajima Kitajima
TKTakako Kihara
Takako Kihara
YKYusuke Kawanaka
Yusuke Kawanaka
AKAki Kido
Aki Kido
KYKotaro Yoshida
Kotaro Yoshida
KYKoichiro Yamakado
Koichiro Yamakado
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Kazuhiro Kitajima1, Takako Kihara2, Yusuke Kawanaka1, Aki Kido3, Kotaro Yoshida4, Yasunari Mizumoto5, Akiko Tomiyama6, Shigeo Okuda6, Masahiro Jinzaki6, Fumi Kato7, Junko Takahama8, Akiko Takahata9, Yoshihiko Fukukura10, Atsushi Nakamoto11, Tetsuya Tsujikawa12, Jiro Munechika13, Yoshimitstu Ohgiya13, Nobuyuki Kawai14, Satoshi Goshima15, Ayumi Ohya16, Yasunari Fujinaga16, Takeru Fukunaga17, Shinya Fujii17, Masahiro Tanabe18, Katsuyoshi Ito18, Takahiro Tsuboyama19, Yuichiro Kanie20, Shigeaki Umeoka21, Shintaro Ichikawa22, Utaroh Motosugi22, Sayaka Daido23, Ayumu Kido24, Tsutomu Tamada24, Mitsuru Matsuki25, Tsuneo Yamashiro26 and Koichiro Yamakado1 1 Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan 2 Department of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan 3 Department of Diagnostic Radiology and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan 4 Department of Radiology, Kanazawa University, Graduate School of Medicine Science, Kanazawa, Ichikawa, Japan 5 Department of Obstetrics and Gynecology, Kanazawa University, Graduate School of Medicine Science, Kanazawa, Ichikawa, Japan 6 Department of Radiology, Keio University School of Medicine, Tokyo, Japan 7 Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan 8 Department of Radiology, Nara Medical University, Nara, Japan 9 Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan 10 Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan 11 Department of Radiology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 12 Biomedical Imaging Research Center, University of Fukui, Fukui, Japan 13 Department of Radiology, Showa University School of Medicine, Tokyo, Japan 14 Department of Radiology, Gifu University Hospital, Gifu, Japan 15 Department of Diagnostic Radiology and Nuclear Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan 16 Department of Radiology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan 17 Division of Radiology, Department of Pathophysiological and Therapeutic Sciences, Tottori University, Tottori, Japan 18 Department of Radiology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan 19 Department of Radiology, National Hospital Organization Osaka National Hospital, Osaka, Japan 20 Department of Radiology, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan 21 Department of Radiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan 22 Department of Radiology, University of Yamanashi, Yamanashi, Japan 23 Department of Radiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan 24 Department of Radiology, Kawasaki Medical School, Okayama, Japan 25 Department of Diagnostic Radiology, Kindai University Faculty of Medicine, Osaka, Japan 26 Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa, Japan Correspondence to: Kazuhiro Kitajima, email: ka-kitajima@hyo-med.ac.jp Keywords: cervical cancer; neuroendocrine carcinoma; small cell carcinoma; large cell carcinoma; MRI Received: February 11, 2020 Accepted: May 14, 2020 Published: October 06, 2020 Copyright: © 2020 Kitajima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Objectives: To investigate neuroendocrine carcinoma (NEC) of the uterine cervix cases for MRI features and staging, as well as pathological correlations and survival. Results: FIGO was I in 42, II in 14, III in 1, and IV in 5 patients. T2-weighted MRI showed homogeneous slightly high signal intensity and obvious restricted diffusion (ADC map, low intensity; DWI, high intensity) throughout the tumor in most cases, and mild enhancement in two-thirds. In 50 patients who underwent a radical hysterectomy and lymphadenectomy without neoadjuvant chemotherapy (NAC), intrapelvic T staging by MRI overall accuracy was 88.0% with reference to pathology staging, while patient-based sensitivity, specificity, and accuracy for metastatic pelvic lymph node detection was 38.5%, 100%, and 83.3%, respectively. During a mean follow-up period of 45.6 months (range 4.3–151.0 months), 28 patients (45.2%) experienced recurrence and 24 (38.7%) died. Three-year progression-free and overall survival rates for FIGO I, II, III, and IV were 64.3% and 80.9%, 50% and 64.3%, 0% and 0%, and 0% and 0%, respectively. Materials and Methods: Sixty-two patients with histologically surgery-proven uterine cervical NEC were enrolled. Twelve received NAC. Clinical data, pathological findings, and pretreatment pelvic MRI findings were retrospectively reviewed. Thirty-two tumors were pure NEC and 30 mixed with other histotypes. The NECs were small cell type (41), large cell type (18), or a mixture of both (3). Conclusions: Homogeneous lesion texture with obvious restricted diffusion throughout the tumor are features suggestive of cervical NEC. Our findings show that MRI is reliable for T staging of cervical NEC. <!--x2o[4121fb2e]-->

3 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KKKei Kimura
Kei Kimura
HTHirotoshi Takiyama
Hirotoshi Takiyama
SYShigeru Yamada
Shigeru Yamada
KIKazuma Ito
Kazuma Ito
MKMizuki Koba
Mizuki Koba
MIMasataka Ikeda
Masataka Ikeda
Background/Objectives: Carbon-ion radiotherapy (CIRT) is a promising treatment option for unresectable locally recurrent rectal cancer (LRRC). However, CIRT is contraindicated in cases where recurrent tumors are attached to the intestine. To address this limitation, we developed a novel treatment strategy involving curative-dose CIRT to recurrent tumors, including the adjacent intestine, without dose constraints, followed by surgical resection of the irradiated intestine. This study aimed to assess the feasibility of this approach. Methods: Patients were eligible for this study if the distance between the unresectable recurrent tumor and the adjacent intestines was less than 3 mm. Between 2019 and 2023, twelve patients were enrolled. CIRT was administered at curative doses of 70.4 or 73.6 Gy (relative biologic effectiveness (RBE)), including the adjacent intestines, without dose constraints. Surgical resection was not intended to excise the tumor itself, but was performed solely to remove the irradiated intestines. Irradiated intestine resection was planned within eight weeks after the completion of CIRT. Results: All patients completed the scheduled treatment course. The median interval between completing CIRT and surgery was 4 (3–8) weeks. No patients experienced acute AEs related to CIRT. Regarding late AEs, two patients developed Grade I sciatic neuralgia, and one patient developed Grade III neuralgia. We considered this symptom, which later resulted in a limp in his left leg, acceptable because this patient could ambulate with assistance. Clavien–Dindo Grade III postoperative complications occurred in one patient. The median follow-up duration was 40 (20–60) months. One patient was diagnosed with in-field recurrence, and three patients were diagnosed with out-of-field recurrence. These patients received reirradiation with CIRT. Four patients experienced lung recurrence, and one patient died from rectal-cancer-specific causes. Conclusions: This novel treatment strategy may provide favorable outcomes for patients with unresectable LRRC. This approach can be applied to the currently accepted indications for CIRT, and we believe that CIRT is a feasible treatment option for future patients.